Polymer-Antigen Conjugated Particles for Controlled Tolerance Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive therapies for inflammatory diseases and disorders, such as autoimmune diseases, are associated with significant side effects and require precise control over antigen encapsulation and release, which is not adequately addressed by existing methods.
Innovation Solution
Development of covalently attached antigen-encapsulated particles with a negative zeta potential, allowing precise control over particle size and antigen loading, reducing burst release and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunosuppressive drugs are used for long-term treatment, then immunosuppression is achieved, but toxic side effects occur
Solution Approach 1:
The patent extracts the antigen-specific component from broad immunosuppression therapy. Instead of using general immunosuppressive drugs that affect the entire immune system, the invention isolates and targets only the specific antigen responsible for the autoimmune response, delivering it through engineered particles to induce tolerance without systemic immunosuppression and its associated toxic side effects.
Solution Approach 2:
The patent introduces engineered particles as intermediaries to deliver antigens specifically to immune cells. These particles act as mediators between the antigen and the immune system, controlling antigen presentation and inducing tolerance through controlled delivery mechanisms rather than direct drug administration.
2Ease of manufacture
If antigen is not covalently attached to particles, then manufacturing is simpler, but antigen encapsulation and release control is inadequate
Solution Approach 1:
The patent applies preliminary action by covalently attaching antigens to particle surfaces before assembly. This pre-conjugation step ensures that antigens are properly positioned and secured on the particles prior to encapsulation, enabling precise control over antigen loading and release characteristics while maintaining manufacturing feasibility through standardized conjugation protocols.
3Ease of manufacture
If antigen release is not controlled, then manufacturing is easier, but burst release occurs causing side effects
Solution Approach 1:
The patent employs preliminary action by pre-conjugating antigens to particle surfaces with controlled orientation and density before encapsulation. This advance preparation enables controlled release kinetics by ensuring antigens are positioned optimally for gradual presentation to immune cells, preventing burst release while maintaining straightforward manufacturing through standardized conjugation procedures.
Solution Approach 2:
The patent utilizes parameter changes by modifying particle properties such as surface charge (negative zeta potential), size, and composition to control antigen release kinetics. These parameter adjustments enable tuned release profiles that prevent burst release while maintaining manufacturing feasibility through controlled variation of formulation parameters.
4Reliability
If antigen-specific tolerance is induced, then autoimmune disease treatment is achieved, but precise antigen control is required
Solution Approach 1:
The patent applies preliminary action by pre-conjugating antigens to particles with controlled orientation, density, and positioning before encapsulation. This advance preparation ensures precise antigen presentation capabilities are built into the particles themselves, enabling reliable antigen-specific tolerance induction while the precision is established during manufacturing rather than requiring complex post-processing.
Solution Approach 2:
The patent introduces engineered particles as intermediaries that mediate between the antigen and immune cells. These particles provide a controlled interface for antigen presentation, translating the need for precise antigen control into a manageable particle design parameter that can be controlled during manufacturing through standardized conjugation and encapsulation protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method induces antigen-specific tolerance, minimizing side effects and achieving controlled antigen release, thereby treating autoimmune diseases and inflammatory disorders effectively.
Implementation Method 1
covalently coupling one or more antigens to one or more carrier polymers to form carrier polymer-antigen conjugates
Data Source
AI summary
The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).